B
urkholderia gladioli are ubiquitous Gram-negative bacteria that are able to occupy diverse environments including soil, plants and the respiratory tract of humans (1) . Although B gladioli have traditionally been recognized as plant pathogens, they are increasingly being reported to cause infections in humans. They are closely related to Burkholderia cepacia complex, which are well known for their ability to cause severe illness in cystic fibrosis patients. Based on poor postlung transplant outcomes, prelung transplant infection/colonization with B cepacia complex is currently an absolute contraindication for lung transplantation at many lung transplant centres in North America (2) .
Case Presentation
A 36-year-old woman with advanced cystic fibrosis (CF) lung disease underwent bilateral lung transplantation in 2007. Her pretransplant history was notable for repeated pulmonary exacerbations involving methicillin-resistant Straphylococcus aureus (MRSA) and Burkholderia gladioli, but without clinically significant sinus disease requiring investigations and/or treatment. Ten months post-transplant, she presented with a right frontal headache. A computed tomography scan revealed severe paranasal sinus disease and she was diagnosed with severe rhinosinusitis. She required extensive sinus surgery, and sinus cultures demonstrated heavy growth of MRSA and scant growth of B gladioli. She was initially treated with intravenous and topical vancomycin. Her immunosuppressive regimen was modified with a reduction in her maintenance prednisone dose and continuation of both tacrolimus and azathioprine. Her initial postoperative course was promising; however, three weeks later, she developed fever, recurrent sinus symptoms and her blood cultures grew B gladioli, which demonstrated in vitro susceptibility to all antibiotics tested including amikacin, tobramycin, meropenem, piperacillin-tazobactam, ciprofloxacin and trimethoprim-sulfamethoxazole. She underwent additional sinus surgery that did not improve her symptoms. Sinus cultures at the time of her second sinus surgery demonstrated light growth of both MRSA and B gladioli. She was placed on intravenous vancomycin, meropenem, ceftazadime, oral trimethoprim-sulfamethoxazole and topical gentamicin. Although she initially improved following this treatment, she went on to develop bilateral purulent otitis media, mastoiditis and petrous bone apicitis ( Figure 1 ). Subsequent sinus cultures demonstrated heavy growth of B gladioli. Her overall clinical condition progressively deteriorated, and she developed persistent B gladioli bacteremia, which developed resistance to all available antibiotics except piperacillin-tazobactam. Unfortunately, despite six months of continuous broad-spectrum intravenous antibiotics and six sinus surgeries, she eventually succumbed to the infection and died 18 months following lung transplantation.
DisCUssion
We contribute to a growing body of evidence that B gladioli infection in CF patients prelung transplant can result in significant posttransplant morbidity and mortality (3-5). Our described case of a CF patient with chronic respiratory infection involving B gladioli prelung transplant tragically resulted in locally invasive sinus disease, persistent bacteremia and death 18 months post-transplant. Although MRSA may have contributed initially to her sinus disease, B gladioli became the primary pathogen because her clinical deterioration correlated closely with heavy growth of B gladioli from the sinuses and subsequent bacteremia. Her sinus infection was exceedingly difficult to control despite continuous intravenous antibiotics in the face of underlying immunosuppression, challenges achieving local source control and eventual development of antibiotic resistance. Interestingly, she did not grow B gladioli in her transplanted lungs and did not demonstrate evidence of allograft dysfunction based on symptoms, spirometry or chest imaging. The present case report follows a recently documented case of a CF lung transplant recipient with a mediastinal abscess due to B gladioli diagnosed postlung transplant that was also difficult to control but eventually responded to a prolonged course of intravenous antibiotics and surgical debridement (3). Although there is general consensus of poor post-transplant outcomes in CF patients harbouring Burkholderia cepacia complex (Bcc) (2), experience with B gladioli infection is limited. Several distinct species constitute what is now referred to as Bcc, with apparent considerable variation with respect to their virulence in CF patients. Based on small studies, some centres have revised their lung transplant eligibility criteria to exclude B cenocepacia-infected patients, while offering transplant to patients harbouring other Bcc genomovars (5) . Although B gladioli are phenotypically very similar to genomovars of Bcc, they are molecularly distinct and, therefore, have been classified as an independent species due to the availability of advanced molecular identification techniques ( The present case adds to the growing body of evidence characterizing considerable morbidity and mortality related to opportunistic B gladioli infection in CF lung transplant recipients. This information suggests that the identification of B gladioli in pretransplant CF patients warrants reconsideration as a possible important relative contraindication to lung transplantation, similar to Bcc.
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